MA-VERISTAT
29.3.2022 16:09:09 CEST | Business Wire | Press release
Veristat , a scientific-minded global clinical research organization (CRO), announced today the formalization of its Strategic Resourcing solution to offer clients the delivery of clinical development and regulatory expertise options fully tailored to their needs. Clients now have access to difficult-to-find experts dedicated to a specific requirement or function to meet their objectives and timelines.
Veristat has been providing demand-based resourcing on a less formalized basis for many years. With the Strategic Resourcing solution, a pipeline of discipline-specific expertise is available and ready to seamlessly integrate into dynamic clinical environments. Veristat resources support work across many disciplines including biostatistics, programming and data management, regulatory consulting, clinical operations including clinical monitoring, project management, site management, as well as medical affairs/safety, medical/regulatory writing, and pharmacovigilance.
“The biopharmaceutical industry is innovating and developing new treatments so rapidly that resourcing demands now outpace the current available talent pool,” commented Patrick Flanagan, Chief Executive Officer at Veristat. “This was a top industry challenge prior to the COVID-19 pandemic, and it remains a top challenge today. Sponsors expect their external partners to continually improve upon the ways in which they can help them achieve true scientific progress delivered with process agility. Our strategic resourcing option provides the necessary flexibility to support a client project in the manner they determine is best.”
Leading the initiative is Bill Donovan, Senior Vice President, Strategic Solutions at Veristat. An industry veteran, Bill has 20+ years of leadership experience partnering with global pharmaceutical and biotechnology companies to accelerate time-to-market results across all stages of clinical trials. Delivering quality specialty resourcing to meet a sponsor’s full spectrum of needs has been a vital component of customer engagements led by Donovan.
“Refining the ways in which we partner with clients to deliver higher efficiencies with accelerated timelines is an ongoing focus for us,” commented Donovan. “Providing drug developers with an agile and specialized resourcing model fully supports this objective. I am thrilled that Veristat has formalized our ability to enhance customer value by allowing sponsors to hire our experts when they cannot find the right talent to support study success.”
Veristat is currently working on projects to treat cancers, rare diseases, neurological disorders, infectious diseases and more. Treatments span vaccines, gene therapies, complex generics, immuno-therapies, and novel drugs. For many clients, Veristat becomes a sponsor’s project team. For others, Veristat provides the medical, scientific, clinical, and statistical expertise to help sponsors advance their therapy into and through the clinical development and regulatory approval process.
Veristat continues to offer its core end-to-end capabilities across the development continuum in both full service and functional service support capabilities as well. Learn more about Veristat’s Strategic Resourcing Solutions here: https://www.veristat.com/services/strategic-resourcing
About Veristat
Veristat , a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 27 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. Our bold thinking, focus, and extensive experience supporting complex drug development in rare and ultra-rare diseases significantly impacted the approval of 12% of the 2021 U.S. Food and Drug Administration (FDA) novel drugs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Joins Athena, a Chainguard-led Industry Coalition to Help Secure Open Source Software in the AI Era24.6.2026 08:30:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has joined Athena, a new industry coalition led by Chainguard, focused on protecting open source software from the rising threat of AI-driven vulnerabilities. Athena brings together leading organizations across the global software ecosystem to address an urgent challenge. As frontier AI models advance, they are increasingly capable of identifying novel vulnerabilities in open source software at machine speed, often faster than traditional disclosure and patching processes can respond. As AI accelerates both software development and the discovery of vulnerabilities, the window between a flaw being identified and being exploited has narrowed sharply. Athena is designed to close this gap through shared intelligence, coordinated action, and pre-disclosure remediation across the ecosystem. The coalition supports vulnerability management end to end, from discovery and analysis to patching, layered mitigations, and upstr
Over Half of Consumers Will Pay More for Brands That Are Transparent About AI Data Use, New Usercentrics Research Finds24.6.2026 08:30:00 CEST | Press release
52% of consumers globally will pay a 7% premium for AI transparency — rising to 73% in Germany. Almost half have already taken an action with a direct revenue consequence. AI transparency has become a commercial differentiator, and it's reshaping where brand revenue is won — or lost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623804294/en/ Over half (52%) of consumers globally will pay more for brands that are transparent about how they use AI with their data at an average 7% premium. In Germany, that figure rises to 73% of consumers willing to pay a 9% premium, the highest of any market. The finding comes from the second annual State of Digital Trust 2026 Report, commissioned by Usercentrics, a leading data privacy technology company, and conducted by Sapio Research across 11,000 consumers in seven markets. The opportunity for brands that act is matched by the cost of inaction. Almost half (47%) of consumers surveyed
Ilkari Expands European Sovereign Infrastructure Operations With Integration of DC North in Croatia24.6.2026 08:00:00 CEST | Press release
Expansion strengthens Ilkari’s multi-region sovereign infrastructure footprint with EU-based operational capacity, DORA-aligned resilience and sovereign cloud capabilities Croatia's largest carrier-neutral 4 MW data centre, DC North, becomes part of Ilkari's European sovereign infrastructure operations The integration adds operational EU-based data centre capacity, carrier-neutral connectivity and sovereign cloud capabilities across Central and Eastern Europe Expansion enhances Ilkari’s ability to serve regulated, sovereignty-focused and data-intensive enterprise environments across Europe Ilkari, a multinational sovereign infrastructure provider, today announced the integration of DC North in Croatia into its European operations, expanding its sovereign infrastructure footprint across the European Union and strengthening its multi-region platform, which includes existing operations in Iceland and Colombia. This press release features multimedia. View the full release here: https://www
Tigo Energy Predict+ Forecasting Platform Helps YASNO Keep Energy Flowing in Ukraine24.6.2026 06:00:00 CEST | Press release
Advanced energy prediction platform, Predict+, enables Ukrainian utility to better maintain grid service through demand surges, highly variable weather, and infrastructure disruptions. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that Ukrainian electric utility, YASNO, is the latest enterprise-tier customer to deploy the Tigo Predict+ platform. The AI Energy platform empowers utility operators to adapt to real-world demand challenges as they balance renewable and baseload generation sources. Predict+ currently manages more than 650 GWh and delivers 97.5% forecast accuracy for utility customers. As the leading provider of electricity, gas, and energy-efficiency solutions in Ukraine, YASNO serves more than 2.5 million households in the Kyiv, Dnipropetrovsk, and Donetsk regions, as well as more than 64,000 business customers. YASNO uses the Predict+ platform in ways that go far beyond typical
MSCI Announces the Results of the MSCI 2026 Market Classification Review23.6.2026 23:42:00 CEST | Press release
MSCI released the results of the MSCI 2026 Market Classification Review. Key takeaways from this year's review include: Reclassification of Bulgaria from Standalone to Frontier Market status Assessment of shareholder transparency and coordinated trading concerns in the Indonesian and Turkish equity markets, acknowledging the announced steps undertaken by both markets to address these matters and noting the continued potential for future consultations on the appropriate treatment of these markets if credible progress is not observed Acknowledgement of the removal of floor prices in Bangladesh, with a caution that any reintroduction could prompt a consultation on reclassification from Frontier to Standalone Market status Ongoing monitoring of the implementation of measures aimed at improving the accessibility of the Korean equity market for international institutional investors Reminder on the reclassification of Greece from Emerging to Developed Market status at the May 2027 Index Revie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom